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Epoxide-Mediated CifR Repression of cif Gene Expression Utilizes
Two Binding Sites in Pseudomonas aeruginosa
Alicia E. Ballok,a Christopher D. Bahl,b Emily L. Dolben,a Allia K. Lindsay,a Jessica D. St. Laurent,b Deborah A. Hogan,a
Dean R. Madden,b and George A. O’Toolea
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA,a and Department of Biochemistry, Geisel School
of Medicine at Dartmouth, Hanover, New Hampshire, USAb
Pseudomonas aeruginosa secretes an epoxide hydrolase virulence factor that reduces the apical membrane expression of ABC
transporters such as the cystic fibrosis transmembrane conductance regulator (CFTR). This virulence factor, named CFTR in-
hibitory factor (Cif), is regulated by a TetR-family, epoxide-responsive repressor known as CifR via direct binding and repres-
sion. We identified two sites of CifR binding in the intergenic space between cifR and morB, the first gene in the operon contain-
ing the cif gene. We have mapped these binding sites and found they are 27 bp in length, and they overlap the 10 and 1 sites of
both the cifR and morB regulatory region and the start of transcription, respectively. In addition, we found that CifR binds to
each repression site with differing affinity. Mutagenesis of these binding sites resulted in a loss of DNA binding in vitro, and mu-
tation of one of these sites in vivo resulted in an increase in transcription of both the cif and cifR genes. We characterized cif and
cifR gene expression in sputum and found that, whereas cif gene expression varied relative to an in vitro coculture control, cifR
gene expression was consistently higher. Analysis of a longitudinal sample of CF isolates from nine patients revealed that Cif
protein was expressed over time, although variably, and these changes could not be linked to mutations in the cifR gene or the
promoters of these genes. Finally, we tested CifR responsiveness to other epoxides and showed that CifR can respond to multiple
epoxides to various degrees.
Pseudomonas aeruginosa is a highly adaptable, opportunistic or-ganism that can infect a variety of plant and animal hosts (32,
43). This versatility allows P. aeruginosa to infect immunocom-
promised humans with great efficiency. In humans, P. aeruginosa
can colonize the skin, urinary tract, eyes, ears, and lungs (15, 19,
29, 30, 41), causing debilitating, even fatal, disease. The hyper-
adaptability exhibited by P. aeruginosa is due, in large part, to the
numerous virulence factors it possesses. These myriad factors in-
clude phosphatases, phospholipases, phenazines, a type 3 secre-
tion system, elastase, and -lactamases (18, 22, 36, 44), which act
in concert to establish P. aeruginosa in its many niches.
P. aeruginosa infection is particularly detrimental in the con-
text of cystic fibrosis (CF) lung infection. CF is an inherited dis-
order in which the individual harbors mutations in both copies of
the CF transmembrane conductance regulator (CFTR). CFTR is
an ABC transporter family protein that moves chloride across the
apical membrane of the epithelia (20). In the lung, chloride secre-
tion is important for maintenance of the airway surface liquid,
which in turn, is required for mucociliary clearance (9). In CF, the
resulting ciliostasis causes a thick mucus layer to form in which a
polymicrobial infection develops (14). P. aeruginosa outcompetes
other bacteria and often becomes the most common, persistent
organism in the CF airway and frequently the cause of mortality
(6, 14). Over the course of this chronic infection, P. aeruginosa will
often decrease or lose expression of several virulence factors (28,
41). This loss of expression can be due to mutations in the gene
coding for the virulence factors themselves or, more often, muta-
tions in the vast regulatory network that controls expression of
these virulence factors (17, 34).
Previously, we characterized a virulence factor, Cif, which is
capable of reducing apical membrane expression of ABC trans-
porters, including CFTR (26, 42). Cif, delivered to epithelial cells
either by direct secretion from the bacterial cell to the extracellular
milieu or via outer membrane vesicles (7), decreases CFTR by
stabilizing the inhibitory interaction between G3BP1 and a deu-
biquitinating enzyme (USP10), resulting in the polyubiquitina-
tion of CFTR and its lysosomal degradation (8). Structural and
biochemical characterization of Cif have revealed that is it an ep-
oxide hydrolase (1, 2, 3). Recently, we have shown that the tran-
scriptional regulator CifR mediates cif gene expression (25). The
cifR gene is adjacent to and divergently transcribed from the three-
gene operon that contains the cif gene. This TetR-family regulator
represses the transcription of the polycistronic transcript encod-
ing the Cif protein by binding to the intergenic region between this
cif-encoding operon and the cifR gene. We previously showed that
in the presence of epibromohydrin (EBH), an inducing epoxide,
CifR releases from the DNA to allow transcription to occur result-
ing in increased Cif production (25). We have shown that the cif
gene is expressed in the lung and that there is variability in cif gene
transcription in clinical isolates (26). However, a better under-
standing of CifR regulation of cif gene expression will assist in the
identification of epoxides and mutations that lead to changes in
this virulence factor’s expression during chronic lung infection.
The goal of the present study was to better characterize the
regulation of the cif gene by CifR. Here, we identify the binding
sites of CifR and place them in the context of transcription of the
cif and cifR genes by characterizing the promoters and transcrip-
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tional start sites of these loci. Furthermore, we identify two puta-
tive CifR recognition sites within these binding regions and dem-
onstrate that mutation of one of these sites results in an increase in
transcription of both the cif and the cifR genes in vivo, as well as the
loss of CifR-DNA binding in vitro. We characterize cif and cifR
gene expression in sputum samples from CF patients and show
differences in transcript level of the message encoded by these
genes. Next, with a clearer picture of CifR-mediated repression of
the cif gene, we characterize Cif expression in multiple clinical
Pseudomonas isolates from CF patients isolated over time. These
data support our hypothesis that CifR-mediated regulation of Cif
is important in the context of lung infection. Toward our en-
deavor of identifying an epoxide inducer of the Cif protein in the
lung, we also characterize cif gene expression in the presence of
several epoxides.
MATERIALS AND METHODS
Strains, plasmids, primers, and culture conditions. The bacterial strains,
plasmids and primers used in the present study are listed in Table S1 in the
supplemental material. Cultures were grown in lysogeny broth (LB) at
37°C. The antibiotics gentamicin (10 g/ml for Escherichia coli and 100
g/ml for P. aeruginosa strain UCBPP-PA14 [PA14]), nalidixic acid (20
g/ml for P. aeruginosa), and ampicillin (150 g/ml for E. coli) were
added to the growth medium for maintenance of plasmids. Yeast was
grown either in yeast extract-peptone-dextrose medium or SD-URA min-
imal medium (Sunrise Science Products) at 30°C. Cloning was performed
using restriction enzymes (NEB) and standard molecular techniques (27)
or Saccharomyces cerevisiae-based recombineering (38).
Mutagenesis of a CifR binding site in P. aeruginosa. To mutate the
morB proximal CifR binding site in P. aeruginosa, two 1-kb regions sur-
rounding the site were amplified with Phusion polymerase (Finnzymes) us-
ing primers containing the mutated CifR consensus sequence (30/5= for Mut,
MorB proximal 6mix F, MorB proximal 6mix R, and 3= rev Mut/30), these
amplicons were cloned into the suicide vector (pMQ30) by yeast-based ho-
mologous recombination (38) and transformed into E. coli S17-1. Conjuga-
tion and counterselection for recombinant P. aeruginosa were performed as
described previously (21, 38) with integrants grown on medium with genta-
micin and nalidixic acid, and mutants selected on medium containing su-
crose. Mutations were verified by sequencing.
EMSA. Electrophoretic mobility shift assays (EMSAs) were per-
formed as described previously [the buffer consisted of 10 mM Tris, 50
mM KCl, 1 mM dithiothreitol (DTT), 2.5% glycerol, 5 mM MgCl2, 50
ng of poly(dI·dC)/l, 0.05% NP-40 (pH 7.5)] (25), with the following
specifications: purified CifR protein (16 nM, unless otherwise speci-
fied) was coincubated with the probe (15 fmol) for 30 min at room
temperature in a volume of 10 l. EBH (1 mM) or unlabeled compet-
itor DNA of the same sequence (300 pmol) was added where indicated.
The probes used here are listed in Table S1 in the supplemental mate-
rial. For Western blot detection of CifR-His bound to DNA, the EMSA
protein was transferred to a nitrocellulose membrane and examined as
described below.
RNA isolation. Strains were diluted 1:100 from overnight cultures
into fresh LB medium, supplemented with 1 mM EBH, as indicated, and
grown at 37°C with shaking. RNA was harvested from 1 ml of triplicate
samples grown to an optical density at 600 nm (OD600) of 1.0. Samples
were pelleted and resuspended in 100 l of 2 mg of lysozyme/ml in TE
buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]), followed by incubation
at room temperature for 5 min to lyse the cells. The RNA was extracted
using the RNeasy kit (Qiagen) according to the manufacturer’s instruc-
tions and tested for DNA contamination by PCR.
cDNA synthesis and qRT-PCR. cDNA was synthesized from 1 g of
total RNA using the QuantiTect reverse transcription kit (Qiagen) ac-
cording to the prescribed protocols. Quantitative reverse transcriptase
PCR (qRT-PCR) was performed using cDNA, primers designed to the cif,
cifR, and rplU genes, a transcriptional control (21), and Maxima SYBR
green qPCR Master Mix (Fermentas). A Bio-Rad iCycler was used to
perform the reactions and data analysis was performed using CFX man-
ager software (Bio-Rad). The data are expressed as picograms of input
cDNA of the gene of interest relative to the rplU gene transcript control.
Sputum sample isolation and transcriptional analysis. Respiratory
sputum samples were collected from four individuals with CF and imme-
diately frozen in a dry-ice– ethanol bath, followed by storage at 80°C for
no more than 2 weeks. The static coculture control was performed as
described previously (26) at a multiplicity of infection of 100:1 and har-
vested after 6 h. To isolate total sputum RNA, samples were thawed on ice,
and the pellet was resuspended in TE buffer and homogenized by passage
through 16-, 20-, and 24-gauge syringe needles. Lysozyme (3 mg/ml) was
then added, and samples were incubated at room temperature for 5 min
with intermittent vortexing. Subsequent RNA isolation steps were per-
formed using a Qiagen RNeasy kit according to the manufacturer’s in-
structions. A Promega RQ1 RNase-Free DNase kit (catalog no. M6101)
was used to remove contaminating DNA. For cDNA synthesis, 450 ng of
total RNA was used as a template in a cDNA synthesis reaction using
random primers [(NS)5], RNaseOUT (Invitrogen, catalog no. 10777-
019), and Superscript III. cDNA synthesis reactions were performed using
the SSIII protocol. Absence of DNA was confirmed by cycle threshold
differences between RT and no-RT controls. qRT-PCRs were performed
using Bio-Rad SsoFast EvaGreen Supermix according to the manufactur-
er’s protocol. The annealing temperatures for rplU, cif, and cifR were 60,
63.7, and 63.7°C, respectively.
5=RACE. RNA for 5= rapid amplification of cDNA ends (5=RACE) was
isolated from P. aeruginosa cultured in LB with EBH. The 5=RACE was
performed using a FirstChoice RLM-RACE kit (Invitrogen) according to
the manufacturer’s instructions. RACE amplification products were li-
gated into pGEM-T vector (Promega), transformed into DH5 E. coli and
selected on medium containing 150 g of ampicillin/ml and 40 g of
X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside)/ml. A min-
imum of three positive clones were sequenced for each transcript.
Western detection of Cif from P. aeruginosa PA14 and clinical iso-
lates. P. aeruginosa was subcultured 1:100 from overnight cultures into 5
ml of LB, grown at 37°C with shaking to an OD600 of 1.0, and then imme-
diately pelleted and frozen at 80°C. For the epoxide induction assay, 1
mM EBH, cyclohexene oxide (CO), styrene oxide (SO), (S)-2-(4-nitro-
phenyl) oxirane (SNO), (R)-2-(4-nitrophenyl) oxirane (RNO), epoxy-
hexane (EH), trans-2,3-epoxysuccinate (TES), cis-2,3-epoxysuccinate
(CES), or glycidol (G) dissolved in dimethyl sulfoxide (DMSO) were
added to culture medium prior to inoculation. Cell pellets were resus-
pended in 1 sodium dodecyl sulfate (SDS) loading buffer (21) and
boiled for 10 min before resolving them by SDS-PAGE. Western analysis
was performed as described previously (10, 21). Membranes were probed
with Cif antiserum (26). Cif protein expression was determined by quan-
tification of pixel density of the Cif band relative to a nonspecific band
using ImageJ.
Cloning of CifR-3C-Decahis expression construct. Generation of a
CifR expression construct containing a 3C-cleavable C-terminal deca-
histidine tag was performed via PCR amplification of the cifR gene
from P. aeruginosa PA14 genomic DNA with the primers BspHI CifR F
and BspHI CifR R and Phusion High-Fidelity polymerase
(Finnzymes). The PCR product was digested with BspHI and ligated
with T4 ligase (NEB) into an NcoI-digested and phosphatase-treated
pET16b vector. Ligated plasmid was transformed into E. coli Top10,
and transformants were selected on LB supplemented with 150 g of
ampicillin/ml. Positive clones were verified by sequencing. This con-
struct generated a CifR protein that possesses a carboxy-terminal deca-
histidine tag, preceded by a cleavage site (LEVLFQGP) for human rhi-
novirus 3C (HRV-3C) protease.
CifR protein purification. CifR protein was purified by immobi-
lized metal affinity chromatography (IMAC), with subsequent re-
moval of the polyhistidine affinity tag. Rosetta 2 (DE3) (Novagen) E.
Ballok et al.
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coli transformed with the CifR expression plasmid was grown in 4 liters
of 2YT broth supplemented with 100 g of ampicillin/ml and 34 g
of chloramphenicol/ml at 37°C. Expression of CifR protein was then
induced at an OD600 of 0.6 by addition of IPTG (isopropyl--D-thio-
galactopyranoside) to 100 M, and cultures were incubated overnight
at 16°C. Cells were harvested from the medium by centrifugation at
5,000  g for 15 min at 4°C. After removal of the supernatant, the cell
pellets were resuspended in 25 ml of lysis buffer per liter of culture
volume. The lysis buffer consisted of 50 mM Tris (pH 8.5), 150 mM
NaCl, 2 mM MgCl2, 1 mM ATP, 25 U of benzonase (Novagen)/ml, and
one EDTA-free complete protease inhibitor cocktail tablet (Roche) per
50 ml. The cells were lysed using a French press, and the lysate was
clarified by centrifugation for 1 h at 4°C in a Ti 45 rotor (Beckman) at
40,000 rpm, which generates an average relative centrifugal force of
125,171  g and a k-factor of 168.1. The supernatant was then passed
over a 5-ml column of Ni-Sepharose resin (GE Healthcare) that had
been preequilibrated with IMAC buffer consisting of 50 mM Tris (pH
8.5), 500 mM NaCl, and 1 mM DTT supplemented with 20 mM imi-
dazole (pH 8.5). After a wash with 10 column volumes of IMAC buffer
supplemented with 77 mM imidazole to remove the unbound mate-
rial, CifR protein was eluted from the resin over a 15-column-volume
gradient running from 248 to 324 mM imidazole in IMAC buffer. The
fractions were pooled, concentrated, and dialyzed into size-exclusion
buffer containing 25 mM Tris (pH 8.5), 150 mM NaCl, 0.1 mM DTT,
and 0.1 mM ATP. The protein concentration was determined by Brad-
ford assay (Bio-Rad), and HRV-3C protease was added to a mass ratio
of 1:10 (protease to CifR). Cleavage of the decahistidine tag proceeded
overnight at 4°C. The HRV-3C protease possesses a noncleavable his-
tidine tag, which is subsequently used to remove it from the sample,
along with any uncleaved CifR protein, by passage over a 5-ml column
of Ni-Sepharose resin (GE). The flowthrough was collected, and
cleaved CifR protein was further purified using size-exclusion chro-
matography (SEC) with a HiLoad Superdex 200 Prep-Grade 26/60
column (GE Healthcare) using size-exclusion buffer. The mature CifR
protein was concentrated using a stirred-cell concentrator with a
3,000-molecular-weight cutoff (Pierce) and dialyzed into 10 mM Tris
(pH 8.5), 50 mM KCl, 1 mM DTT, and 5 mM MgCl2.
RESULTS
Evidence for two CifR binding sites. We have previously reported
that purified CifR was capable of binding to the intergenic region
between the cifR gene and morB, the first gene in the cif operon
(Fig. 1A) (25). CifR binding to the intergenic region was previ-
ously demonstrated by EMSA using a purified hexahistidine-
tagged CifR protein (25). For the present study, we generated a
new CifR expression system using a pET16b expression vector
containing a C-terminal cleavable decahistidine tag. This new
construct allowed us to more easily isolate pure, concentrated,
CifR protein that does not contain extraneous peptides. Analytical
SEC suggests this protein (predicted size, 21.75 kDa) is a mono-
mer in solution (Fig. 1B), unlike the related TetR which forms a
dimer (31).
Incubation of this protein with the intergenic region resulted
in a detectable shift of the biotinylated DNA fragment by EMSA
(Fig. 1C). This interaction could be disrupted upon addition of the
Cif substrate EBH (Fig. 1C, rightmost lane). This finding is con-
sistent with previous work showing that CifR responds to this
epoxide through release of DNA, as observed by EMSA, and via
transcriptional derepression, as shown by in vivo studies (25). In-
terestingly, upon addition of increasing concentrations of CifR,
we observed two migrating species, the slower of which became
the dominant band at the highest concentrations of CifR (Fig. 1C).
The detection of two bands by EMSA suggested that there may be
more than one CifR binding site in this region.
Identification of two separable CifR binding sites within the
cifR-morB intergenic region. To test the hypothesis that CifR was
binding to two sites in the intergenic space between the cifR gene
and the morB operon, we generated a set of three overlapping
biotinylated DNA fragments spanning this region (Fig. 2A).
EMSA analysis showed that CifR was capable of EBH-responsive
binding to the two DNA fragments most proximal to the cifR gene
(regions 2 and 3) but could not bind to the scrambled region 3
FIG 1 CifR, a monomer in solution, binds to the intergenic region between the cifR gene and morB operon. (A) Depiction of the operon containing the cif gene.
The cifR gene is divergently transcribed from this operon, which includes a gene coding for a predicted morphinone reductase (morB), a putative MFS transporter
(PA14_26110), as well as the epoxide hydrolase-encoding cif gene. The double-stranded DNA (dsDNA) fragment used in Fig. 1C is indicated and labeled as the
“intergenic DNA fragment.” (B) SEC of CifR shows a peak at 228.0 ml, corresponding to a predicted molecular mass of 26.9 kDa. Since the predicted molecular
mass of recombinantly expressed CifR protein is 21.9 kDa, these data indicate that CifR is monomeric in solution. The size markers used are indicated in the
figure. (C) EMSA of CifR with a biotinylated intergenic region dsDNA fragment reveals increased binding with increasing concentrations of CifR (2-fold from
5 to 512 nM). A second, slower-migrating band appears with higher concentrations of CifR. The CifR-DNA interaction can be effectively disrupted by
coincubation with 1 mM EBH (rightmost lane).
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sequence DNA fragment or the region 1 DNA fragment (Fig. 2B).
Only one shifted species was observed for either of the region 2 or
region 3 DNA fragments, even with excess CifR (see Fig. S1 in the
supplemental material), suggesting the presence of a single CifR
binding site on each fragment.
To verify that CifR recognized two separable binding sites,
smaller biotinylated DNA fragments were designed that contained
no overlapping regions. These oligonucleotides were designated
“cifR proximal” and “morB proximal” (Fig. 2A). Both of these
probes could be bound by CifR, and the binding was abrogated by
the addition of 1 mM EBH or a 200-fold molar excess unlabeled
DNA fragment of the same sequence, indicating the interaction
was sensitive to the inducer of cif gene expression (Fig. 2C). These
data support our hypothesis that CifR binds to two sites in the
cifR-morB intergenic region.
Determination of the relative affinities of CifR for each bind-
ing site. Given that we had initially observed differences in bind-
ing ability using the region 2 and region 3 probes (see Fig. S1 in the
supplemental material), we tested whether there were differences
in the relative affinities of CifR for both the cifR proximal and the
morB proximal 36-bp fragments, using a previously reported
method (24). Using a gradient of unbound biotinylated DNA
fragments as the reference (Fig. 3A and C), we analyzed the per-
centage of DNA bound by increasing concentrations of CifR and
quantifying band intensity. Using this method, we determined
that CifR has apparent affinities of 37  9 nM and 437  65 nM,
respectively, for the cifR proximal and morB proximal sites. These
data show that the CifR-DNA interactions at both sites are in line
with characterized TetR family DNA-binding proteins (see Dis-
cussion).
CifR binds a 27-bp fragment of DNA to repress transcrip-
tion. We surmised that CifR recognized and bound a region
smaller than 36 bp, like many other regulators in this family (33).
Thus, we decided to further define the binding region for CifR by
designing several smaller DNA fragments from the cifR and morB
proximal oligonucleotide sequences. These smaller DNA frag-
ments did not show any shift by EMSA (data not shown); how-
ever, combinations of these probes, fused by PCR, allowed us to
narrow down the binding site to an approximate region of 30 bp
for each site.
Using this sequence information, we designed unlabeled DNA
fragments (to obviate any potential interference from biotin) of 27
bp to test for interactions with CifR using two approaches. First,
using an uncleaved decahistidine-tagged CifR, we performed an
EMSA and detected CifR-bound to DNA by Western blot analysis
using an anti-His antibody (Fig. 4A). With this technique we were
able to visualize CifR bound to the 36-bp intergenic sequences, as
well as the new 27-bp fragments. No binding was observed with a
scrambled sequence control (Fig. 4A), indicating CifR recognized
a specific sequence within that region. Next, we verified this inter-
action by testing whether a 200-fold excess of unlabeled 27-bp
fragment was capable of competing CifR from a biotin-labeled
36-bp fragment. As can be seen in Fig. 4B, both of the unlabeled
36- and 27-bp fragments are capable of competing for CifR bind-
ing. However, scrambled versions of the 27-bp sequence do not
compete CifR binding from the biotinylated 36-bp DNA frag-
ments. In addition, Western analyses with smaller DNA fragments
(16 to 25 bp) resulted in a noticeable reduction in binding by CifR
(data not shown). These data suggest that CifR is capable of bind-
ing these 27-bp fragments (Fig. 4C).
Characterization of the cifR gene and morB operon promot-
ers. Given the location of the CifR repression sites identified in the
intergenic region between the cifR gene and the morB operon, it
became necessary to provide a context for these data in relation-
ship to the respective transcriptional start sites. Therefore, we uti-
lized 5=RACE to map the start sites for the cifR gene and morB
operon transcripts, as indicated in Fig. 4C.
We next used the promoter prediction software, BPROM
(SoftBerry), to identify the 10 and 35 sites for each sequence.
As can be seen in Fig. 4C, there is significant overlap of these two
promoter sequences, with the 35 position of each transcript sep-
arated by only one base from the 10 position of the opposite
FIG 2 CifR binds to two distinct sites in the region between the cifR and morB genes. (A) Sequence of cifR-morB intergenic region. Predicted translational start
sites for cifR (left) and morB (right) are indicated in boldface. Black bars indicate DNA fragments used in EMSA analyses and competition studies. (B) EMSA with
DNA fragments spanning the intergenic region revealed CifR bound to two DNA fragments (regions 2 and 3). No binding is observed in the presence of 1 mM
EBH or with a biotinylated scrambled sequence. (C) EMSA with two nonoverlapping DNA fragments exhibits CifR binding. No binding is seen with excess
unlabeled competitor of identical sequence or 1 mM EBH. A “	” indicates the addition of the specified component.
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transcript. With this information, we were able to determine that
the 27-bp regions likely bound by CifR overlap the 10 and 	1
sites of each transcript (Fig. 4C).
Characterization of the CifR recognition sequence. While
analyzing the promoters of each of these sequences, we identified
a 18-bp sequence located between the 10 and 	1 sites of each
transcript that showed a high degree of conservation on the tem-
plate strand (Fig. 4C and Fig. 5A). We hypothesized that this se-
FIG 3 Apparent Kd determination by EMSA. (A) EMSA with the cifR proximal binding site. (Left side) Examples of DNA fragment gradient; (right side) DNA
fragments with increasing concentrations of CifR. (B) Affinity of CifR for cifR proximal site. The data are plotted as the log complex/free biotinylated DNA versus
CifR concentration. The apparent equilibrium is at 37 nM. (C) Representative EMSA with the morB proximal binding site. (D) Affinity of CifR for morB proximal
binding site. The apparent equilibrium for CifR to this binding site is 437 nM. These differences are statistically significant (P  0.01).
FIG 4 CifR binds two 27-bp regions overlapping the 10 and 	1 sites of the morB and cifR promoters. (A) Western detection of decahistidine-labeled CifR on
an EMSA with unbiotinylated DNA fragments. (B) Competition-based EMSA. The CifR/36-bp DNA interaction was competed with a 200-fold molar excess of
unlabeled 36-bp, 27-bp, or scrambled 27-bp DNA fragment. (C) Map of intergenic region. The 5=untranslated region (5=UTR) and translational start sites are
indicated with arrows. The putative CifR binding site (boxed), conserved sequences (boldface), and the predicted 10 and 35 promoter motifs (gray text,
underlined) are indicated for each promoter.
CifR Regulation of cif
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quence, located within the 27-bp binding region, was recognized
by CifR. To test this hypothesis in vitro, we generated biotinylated
versions of the 36 nucleotide fragments that contained a 6-bp
scramble in the center of the 18-bp conserved sequence (desig-
nated “6-mix”, Fig. 5A). We then performed an EMSA comparing
the native sequence to the 6-mix sequence (Fig. 5B). Although
CifR was able to bind the native sequence of each of these binding
sites, we did not observe any binding to the probes with the 6-bp
alteration, suggesting that CifR recognizes a specific sequence for
binding.
The EMSA analysis provided important information regarding
CifR sequence recognition. However, these data could not lend
insight into how each of these sequences modulate transcription
of the cifR gene and the morB operon in vivo. Our next step was to
verify the physiological role of these binding sites by altering them
in vivo and analyzing changes in cifR and cif gene expression. We
approached this analysis by introducing the same 6-bp changes
from the EMSA oligonucleotides onto the chromosome by ho-
mologous recombination. Unfortunately, despite repeated at-
tempts to introduce a cifR proximal 6-mix mutation, we were
unable to isolate this mutant. We were successful at introducing
the morB proximal 6-mix mutation.
We first analyzed Cif expression in the morB proximal 6-mix
mutant by Western analysis. This analysis was done from cell pel-
lets as a measure of Cif protein production, although secreted Cif
shows a similar trend (see Fig. S2 in the supplemental material).
Figure 5C shows that, compared to the wild type, the 6-mix mu-
tant has an increase in Cif protein levels, suggesting that mutating
this 6-bp region does have an effect on Cif protein expression in
vivo. This mutant does not appear to express the Cif protein as
highly as a cifR deletion mutant (Fig. 5C).
Next we quantified gene expression changes in the presence or
absence of 1 mM EBH by qRT-PCR (Fig. 5D). The 6-mix mutant
showed a 5-fold increase in cif gene expression relative to the wild
type. There is a further 4-fold increase in expression upon addi-
tion of EBH to wild-type levels, supporting our hypothesis that
CifR responds to the presence of this epoxide. Interestingly, the
cifR deletion mutant also exhibited a small, but significant 2-fold
increase in cif gene expression in the presence of EBH, indicating
additional, non-CifR-dependent, epoxide-mediated regulation of
cif gene transcription.
Since the CifR repression site between the 10 and 	1 of morB
is very close to the predicted 35 promoter element of the diver-
gently transcribed cifR gene, we decided to test the expression of
the cifR gene in this 6-mix mutant background (Fig. 5E). Com-
pared to the wild type, there is a 7.5-fold increase in cifR transcript
in the 6-mix mutant. Again, upon the addition of 1 mM EBH, this
difference is eliminated. Together, these data show that CifR re-
presses transcription of both transcripts via the morB proximal
site in vivo and suggest that CifR binding at both sites is required
for complete repression by CifR. In addition, any transcriptional
differences in expression of the cif gene-containing operon and the
cifR gene due to mutation of the binding site are eliminated by
addition of epoxide. This shows that the primary mechanism of
repression at this locus is likely the same for both transcripts and is
mediated by CifR and its epoxide effector.
Characterization of cif and cifR gene expression in CF spu-
tum. We have shown CifR expression appears to be important for
FIG 5 Mutation of conserved sequence alters CifR binding in vitro and in vivo. (A) Comparison of template strand, cifR proximal, and morB proximal binding
site-conserved sequences. Nucleotide differences between the two binding sites are boxed. Mutated sequences are listed below with changes highlighted (gray,
underlined). (B) EMSA with mutated DNA fragments. A “	” indicates the addition of the specified component. (C) Western detection of Cif in strains grown
with or without EBH. 6-mix indicates P. aeruginosa with a 6-bp sequence change in the morB promoter, indicated above (Fig. 5A). (D) Quantitative RT-PCR of
cif gene transcription in strains with or without EBH. The data are expressed as picograms input RNA relative to a transcriptional control (rplU). Significance:
a, statistically significant difference between the wild type (WT) and 6-mix in the absence of EBH (P 
 0.0008); b, statistically significant difference between the
WT and the cifR deletion strain (P 
 0.0002); and c, statistically significant difference in cif transcription in the cifR deletion strain with or without EBH (P 

0.0003). (E) qRT-PCR of cifR transcription in WT and the 6-mix mutant strain. Significance: a, statistically significant difference between WT and 6-mix (P 

0.0317); ns, not significant.
Ballok et al.
5320 jb.asm.org Journal of Bacteriology
Cif modulation under in vitro conditions, but CifR expression has
not been demonstrated in RNA extracted from patient samples.
Previously, we had detected cif transcript from the sputum of CF
patients (25). We decided to test whether we could detect cifR gene
expression in sputum and whether this could be correlated to cif
gene expression. For this analysis, we compared gene expression
between bacterial RNA isolated from sputum to that observed in
P. aeruginosa grown on CFBE41o human-derived airway epi-
thelial cells. The cif and cifR transcripts were detected in all four
sputum samples tested (Fig. 6). The relative abundance of both
transcripts varied from sample to sample, suggesting that expres-
sion is variable between patients. In general, greater cif gene tran-
scription correlated with greater cifR gene transcription, similar to
the relationship we have described in vitro. Surprisingly, cifR gene
expression was consistently higher in the sputum samples than in
the coculture control, suggesting derepression of this gene in the
sputum samples.
P. aeruginosa isolates from CF patients maintain Cif and
CifR expression and/or regulation over time. Often over the
course of CF lung infection, P. aeruginosa adapts to its environ-
ment through phenotypic and genetic changes. These adaptations
can include a transition to mucoidy, the loss of quorum sensing,
and downregulation of several virulence factors (16, 17).
In our transcriptional analysis of sputum samples, we observed
variability in cif gene expression and relatively high levels in cifR
gene expression. We have previously reported similar variability
in cif gene expression among clinical isolates (26). We suspected
that this variability was due to a temporal loss of Cif expression.
We decided to test whether we could link changes in Cif expres-
sion to changes in the newly characterized promoter region of the
cifR gene. For the present study, we analyzed Cif expression from
36 clinical strains of P. aeruginosa that were isolated from eight CF
patients during their lifetimes (5).
As shown in Fig. 7A, Cif protein expression (in the absence of
the epoxide inducer) was variable, even among clinical isolates
collected from the same patient at the same time point (see Table
S2 in the supplemental material). In general, the clinical isolates
displayed lower production of Cif relative to the laboratory strain
P. aeruginosa PA14 (PA14, Fig. 7A; see also Table S2 in the sup-
plemental material). It is important to note that Cif protein was
expressed in all strains tested. Cif expression did not decrease over
time, suggesting there was no strong negative selection against
expression of this virulence factor as strains adapted to the CF
lung. Colony morphology also appeared to have no bearing on Cif
expression since classic, mucoid, and dwarf isolates had represen-
tatives of high and low expression (see Table S2 in the supplemen-
tal material).
Next, we attempted to link the differences in expression to
mutations in the intergenic region between cifR and the morB
operon or in the cifR gene sequence. These data are summarized in
Fig. 7B. Sequence analysis of the 36 isolates identified a number of
point substitutions in the specified sequences. Many of these were
synonymous substitutions or did not correspond to nucleotide
changes likely to affect the promoters. All isolates contained an
M157V amino acid sequence variant present in P. aeruginosa
PAO1 that does not inhibit CifR function (Fig. 7C and see Table S2
in the supplemental material). One mutation was identified in the
final base (5=-3=) of the morB proximal CifR binding site, but this
did not correspond to an increase in Cif protein levels (see Table
S2 in the supplemental material). We did identify two nonsynony-
mous alanine-to-serine mutations in the CifR sequence within the
predicted ligand-binding domain. These mutations did not ap-
pear to ablate CifR repression (see Table S2 in the supplemental
material and Fig. 7C), but we decided to test whether these muta-
FIG 6 Comparison of cif and cifR gene expression in CF sputum. Quantifica-
tion of the cif gene (light gray) and cifR gene (dark gray) transcripts in sputum
from four CF patients was performed. Expression is normalized to the levels
observed in P. aeruginosa PAO1 cocultured on CFBE41o airway epithelial
cells.
FIG 7 Cif expression in clinical isolates varies over time. (A) Example of
cell-associated Cif protein expression from clinical isolates compared to the
lab strain P. aeruginosa PA14 (PA14, left) as determined by Western blotting.
Numbers indicate the time in years from when the first P. aeruginosa isolate
was harvested. These experiments were performed in the absence of the epox-
ide inducer. (B) Map of mutations, identified in 36 isolates screened. The
predicted DNA-binding region is indicated in gray (HTH, helix turn helix).
White arrows indicate synonymous mutations in the coding sequence or a
mutation in the intergenic region not assigned a function. Gray arrows indi-
cate nonsynonymous mutations or those that might impact gene expression.
(C) Cif protein expression with (	) or without () EBH in P. aeruginosa
PA14, P. aeruginosa PAO1, and isolates harboring the mutations described in
panel B. t40c is a noncoding mutation that changes the final nucleotide in the
morB proximal binding site. (D) Cif protein expression in wild-type P. aerugi-
nosa PA14 in the presence of epoxides shown as Cif signal intensity relative to
a nonchanging, nonspecific band (NSB, not shown). DMSO, negative control;
CO, cyclohexene oxide; SO, styrene oxide; SNO, (S)-nitrophenyl oxirane;
RNO, (R)-nitrophenyl oxirane; EH, epoxyhexane; TES, trans-epoxysuccinate;
CES, cis-epoxysuccinate; G, glycidol.
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tions in CifR could negatively impact the ability of CifR to respond
to an epoxide stimulus. Western analysis of clinical isolates grown
in the presence of EBH all showed a sharp increase in Cif protein
production, similar to P. aeruginosa PA14, suggesting no impair-
ment of ligand response, even at lower concentrations of the in-
ducer (Fig. 7C and see Fig. S3A in the supplemental material).
These data support the hypothesis that both Cif and CifR expres-
sion and the function of the CifR protein are maintained in lung
isolates of P. aeruginosa over time.
Effect of epoxides on Cif induction. Since we could not link cif
and cifR gene expression changes to mutation, we suspected that
CifR was responding to an epoxide inducer in the lung. Our group
has reported on the ability of the Cif protein to hydrolyze epox-
ides, including EBH and cis-stilbene oxide (3, 25, 26). Although
these observations have allowed us to verify the epoxide hydro-
lase activity of the Cif protein, these substrates are unlikely to
be found in the context of CF lung infection. In addition, no
other epoxide except for EBH has been reported to induce Cif
protein expression in vivo (25). We suspect that a better under-
standing of which kinds of epoxides are able to induce Cif
protein expression through CifR may provide insight into the
identity of the inducer(s) of Cif protein expression in the lung.
Thus, we characterized the ability of the several different non-
endogenous epoxides to induce Cif protein expression. These
data are summarized in Fig. 7D.
As previously shown, Cif protein expression is strongly in-
duced in the presence of EBH relative to a DMSO control (Fig.
7D). The additional epoxides were able to induce expression to
various degrees (Fig. 7D). SO was capable of increasing Cif protein
levels to a degree similar to EBH. Others, such as CO, RNO, and
SNO, were able to moderately induce Cif expression, while the
remaining epoxides exhibited little induction. We tested a selec-
tion of these epoxides with the clinical isolates carrying the ala-
nine-to-serine substitutions and observed no alteration in epox-
ide-mediated induction (see Fig. S3B in the supplemental
material). Thus, these data indicate that CifR is capable of re-
sponding to multiple, distinct epoxide ligands.
DISCUSSION
Over the past decade, the study of P. aeruginosa pathogenesis has
shifted from virulence factor identification to the characterization
of virulence factor modulation and expression during infection.
Much work has been done in recent years describing the regula-
tors and regulatory pathways involved in lung infection such as
LasR, RhlR, MucA, and cyclic-di-GMP signaling, since these sys-
tems are often the first perturbed or mutated during chronic in-
fection (11, 13, 17, 39). We characterized here the modulation of
the virulence factor, Cif, by its regulator, CifR.
We have previously reported the discovery of CifR, a TetR-
family regulator that is encoded by a gene that is adjacent to, and
divergently transcribed from, the cif gene-containing operon and
that binds directly to the intergenic space between the cifR gene
and the morB operon (25). In the present study we show CifR
binds to two distinct sites within this intergenic region, overlap-
ping the 10 and 	1 promoter elements for both the cifR gene
and the morB operon. Binding at a similar promoter-proximal site
has been shown recently for another TetR-family regulator,
RamR, of Salmonella enterica (4), in contrast to other family mem-
bers that have been shown to bind at a location more distal to the
transcriptional start (33, 35). However, these repressors have all
been shown to bind at a single site to mediate repression of the
operon as either a dimer or a dimer of dimers (4, 33, 35), whereas
CifR binds at two distinct operators, separated by 28 bp, to control
the expression of divergently transcribed loci. The auto-regulation
exhibited by CifR, common in the TetR family, is believed to be a
feedback control mechanism that ensures optimal repressor con-
centration (33). Mutagenesis of the operator proximal to morB
resulted in an increase in expression of both the cif and cifR tran-
scripts, suggesting that both sites are required for complete repres-
sion of each of these genes. Although the morB proximal binding
does not directly overlap with the cifR promoter, the 35 position
is separated by 1 base from the 10 position of the predicted morB
promoter (Fig. 4C). CifR bound to the morB promoter region may
provide enough steric interference to prevent RNA polymerase
binding the cifR promoter. Alternatively, CifR may work at these
two binding sites cooperatively to repress both transcripts, and
mutating one of these binding results in the loss of such coopera-
tivity, although we have no in vitro data to support this possibility.
Indeed, our data suggest that CifR is a monomer in solution.
Analysis of the CifR binding sequence revealed that CifR binds
a 27-bp region of DNA with high affinity. Other TetR-family reg-
ulators, such as AcrR of E. coli and QacR of Staphylococcus aureus,
have operators of similar lengths (24 and 28 bp, respectively) (37,
40). These regulators bind their operators as dimers of dimers,
whereas TetR binds a smaller, 15-bp sequence as one dimer (33).
The nature of CifR-DNA binding is the subject of ongoing study.
We also determined the apparent Kd of CifR for the cifR and
morB proximal binding sites to be 35 and 512 nM, respectively.
The 35 nM affinity of CifR for the cifR proximal binding site is
consistent with other TetR-family proteins, such as AcrR (20.2
nM) and CmeR (88 nM) in their affinity for their binding sites (23,
35). The apparent dissociation constant for the morB proximal site
is higher than that of the cifR proximal site, which may be attrib-
utable to differences in the sequences in these sites (Fig. 4C and
5A). Changes in the sequence of the RamR binding site of S. en-
terica also resulted in dramatic differences in DNA binding (4),
highlighting the importance of sequence conservation. Finally, ge-
nome-wide sequence analysis revealed no other predicted CifR
binding sites, suggesting that CifR may only regulate the morB
operon and the cifR gene via these sites.
Analysis of cif gene expression under laboratory conditions
showed that CifR-mediated repression was important for main-
taining low-level expression under noninducing conditions. We
decided to test whether this was true in the context of the CF lung
by attempting to detect cifR transcript in CF sputum and correlat-
ing that to cif gene transcription. These data show that the cifR
gene is expressed, suggesting this regulator may be derepressed in
the lung. Increases in cif gene expression corresponded to in-
creases in the cifR gene transcriptional level showing that the reg-
ulatory relationship observed in vitro is likely paralleled in vivo and
furthermore suggesting that there may be an epoxide inducer in
the lung.
The sputum sample transcriptional data suggested that cif gene
transcription appears variable. Previous expression analysis of a
few clinical isolates had also shown that cif gene expression is
variable (26), indicating heterogeneity in the lung environment
similar to what is seen with other virulence factors (12, 16). We
attempted to address these questions by exploiting a collection of
clinical isolates of P. aeruginosa from a longitudinal study of CF
patients. We observed changes in Cif protein expression from
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these isolates; however, the expression did not decrease but in-
stead remained variable over time. This variability could not be
linked to mutations in the promoter or cifR gene sequences, since
many of the mutations were present in all isolates from the same
patient. In addition, colony morphology could not be linked to
changes in expression. These data may suggest that there are other,
yet-to-be-discovered regulatory factors involved in cif gene and
Cif protein expression. Supporting this hypothesis, our cifR dele-
tion strain exhibits a small but significant increase (2-fold) in cif
gene transcription in the presence of EBH (Fig. 5D), suggesting
the presence of another epoxide-sensitive regulator. Ongoing re-
search is aimed at identifying additional factors involved in cif
gene regulation.
We have previously shown that Cif is an epoxide hydrolase and
CifR responds to the epoxide EBH by a reduction in DNA binding,
thus permitting transcription (25, 26). In the present study we
attempted to test the diverse types of epoxide signals potentially
bound by CifR through the identification of epoxides capable of
inducing Cif expression (i.e., inducing the loss of CifR-DNA bind-
ing). There were clear differences in the ability of each of these
epoxides to induce Cif protein expression, with some much better
at inducing expression than others. It is possible that this result is
due to differences in the CifR ligand site or membrane permeabil-
ity of these compounds. Either way, P. aeruginosa expresses Cif
and CifR in the lung, perhaps in response to an epoxide trigger,
which must be able to traverse the bacterial membrane and target
CifR. These epoxide findings are important, since they will facili-
tate future research into the Cif enzyme substrate in the context of
the human lung.
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